Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd. unveiled the expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the United States by raising the supply of high-quality affordable insulins.
This long-term agreement between the two companies creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing marketing approval (a private label agreement).
Civica will distribute, promote, and sell the medicine in the United States under a separate Civica label and trade dress, and in California, the product will carry the CalRx brand.
Biocon Biologics will continue to directly commercialize Biocon Biologics’ own Insulin Glargine-yfgn medicine, which was approved by the U.S. Food and Drug Administration (FDA) in July 2021 as the first interchangeable biosimilar.
Executive Statement
According to Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally. By extending their collaboration with Civica, Inc. to include Insulin Glargine, they are building on their differentiated approach to serving and enhancing patient access—by retaining their direct commercialization and through this strategic partnership. This collaboration enables them to reach underserved populations through new channels in direct alignment with their mission.
